Intellia Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NTLA | CRSP | EDIT | SCTX | SANA | PRME | |
|---|---|---|---|---|---|---|
| Market cap | 1.72B | 5.02B | 417.74M | 317.67M | 766.36M | 901.44M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.8 | -14.4 | -3.6 | -4.6 | -4.6 | -5.6 |
| Price/book | 2.4 | 3.0 | 4.0 | -0.3 | 5.0 | 22.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −12.60% | −8.54% | +1.12% | −11.54% | −36.79% | +18.90% |
| Today | +3.79% | +3.57% | +4.62% | +3.58% | +4.92% | +9.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NTLA news ›Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran Medical Congress Presentations
Investing News Network Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran Medical Congress Presentations - Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of n
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late
Shares of Intellia Therapeutics Inc. (NTLA) soared in Monday’s pre-market trade after the company reported positive Phase 3 trial results in its therapy for a rare genetic condition. Intellia Therapeutics shares were up more than 9% before…
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)
Posted by Tristan Rich on Oct 24th, 2026 Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
More from 1 other outlet
Intellia Therapeutics Receives FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran For Hereditary Angioedema
Intellia Therapeutics, Inc. announced the U.S. Food and Drug Administration has accepted the Biologics License Application for lonvo-z and granted the BLA Priority Review with a Prescription Drug... Food and Drug Administration (FDA) has…
Intellia Therapeutics, Inc. announced that it expects to receive $400 million in funding
Intellia Therapeutics, Inc. announced that it has has entered into a $400 million credit agreement with new lenders, OrbiMed Royalty & Credit Opportunities V, LP, fund managed by OrbiMed Advisors LLC... announced that it has has entered…
Transcript : Intellia Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026
Presentation Operator MessageOperator Hello, and welcome to Intellia Therapeutics Second Quarter Conference Call. My name is Chloe, and I will be your conference operator today. Please be advised Transcript : Intellia Therapeutics, Inc.,…
What kind of company is Intellia Therapeutics (NTLA)? — A drug discovery company with a gene-editing therapy currently under regulatory review
[Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 12 (Final Episode) / 12 Episodes Total] How to look at this: What are companies "under regulatory review" waiting for? ① What does this company do? ② What type of company…
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)
Posted by Danessa Lincoln on Oct 19th, 2026 Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) and Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two…
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy
Shares of Intellia Therapeutics, Inc. (NTLA) surged 35% overnight heading into Monday as retail excitement peaked ahead of a Phase 3 readout that could mark the first late-stage validation of an in-vivo CRISPR gene-editing platform. NTLA…
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Average Target Price of $20.72
Posted by Michael Walen on Oct 17th, 2026 Check Out Our Latest Report on Intellia Therapeutics NASDAQ NTLA opened at $11.42 on Friday. The company has a market cap of $1.60 billion, a PE ratio of -3.40 and a beta of 1.80. The stock’s 50…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com12
- defenseworld.net5
- themarketsdaily.com3
- stocktwits.com2
- globenewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 28 articles, not a forecast.